A5058765211- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Mesenchymal stem cell research
- Telomeres, Telomerase, and Senescence
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- T-cell and Retrovirus Studies
- Sarcoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyotrophic Lateral Sclerosis Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Multiple and Secondary Primary Cancers
- Cancer therapeutics and mechanisms
European Institute of Oncology
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2024
University of Milan
2004-2024
Ripamonti
2017-2024
A. O. Ordine Mauriziano di Torino
2009-2019
University of Turin
2008-2018
Novartis (China)
2017
Bristol-Myers Squibb (Switzerland)
2017
Janssen (Belgium)
2017
Thermo Fisher Scientific (United Kingdom)
2017
We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by myeloablative treatment and bone marrow transplantation, with methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin (MACOP-B) as initial or salvage for adults diffuse large-cell lymphoma.
Purpose The Sequential Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial ( ClinicalTrials.gov identifier, NCT01458548) established sequential treatment with four cycles rituximab followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy as a standard in the management post-transplant lymphoproliferative disorder (PTLD) identified response to induction prognostic factor for overall survival. We hypothesized that...
Purpose To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on positive positron emission tomography scan performed two doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) cycles (PET2). Patients Methods advanced-stage (IIB to IVB) HL were consecutively enrolled. After ABVD cycles, PET2 centrally reviewed according Deauville five-point scale. randomly assigned four escalated...
Purpose Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of malignancies characterized by poor prognosis. We performed pilot study to investigate the role reduced-intensity conditioning (RIC) followed allogeneic stem-cell transplantation in relapsed or refractory PTCLs. Patients and Methods have conducted phase II trial on 17 patients receiving salvage chemotherapy RIC hematopoietic cells. The regimen consisted thiotepa, fludarabine, cyclophosphamide. acute graft-versus-host...
PURPOSE: To describe molecular monitoring of minimal residual disease in patients with myeloma who have achieved complete remission (CR) after autologous or allogeneic transplantation hematopoietic cells. MATERIALS AND METHODS: Clonal markers based upon the rearrangement immunoglobulin heavy-chain genes were generated for each patient and used polymerase chain reaction (PCR) detection Fifty-one entered program 36 CR. After transplantation, was performed on 29 (15 14 transplants) had markers....
The optimal treatment of primary mediastinal large B-cell lymphoma (PMLBCL) is still undefined. In the absence randomised studies, we retrospectively analysed: (a) effectiveness two chemotherapy regimens (CHOP vs MACOP-B/VACOP-B) in complete remission (CR) achievement and event-free survival (EFS) (b) role involved-field radiotherapy (IF-RT) as consolidation. From 1982 to 1999, 138 consecutive patients affected by PMLBCL were treated 13 Italian institutions with CHOP (43) or MACOP-B/VACOP-B...
The frequency of ras (H-, K-, and N-ras) c-myc oncogenes was investigated in multiple myeloma (MM). By means the polymerase chain reaction (PCR)/oligonucleotide hybridization method, DNA from 56 tumor biopsies analyzed for presence activating mutations involving codons 12 61 H-, N-ras genes codon 13 gene. Mutations, N- or K-ras genes, were detected 18 (32%) cases which 12/43 (27%) at diagnosis 6/13 (46%) after treatment. In some cases, affecting different alleles detected. Direct nucleotide...
Many lymphoma and myeloma patients fail to undergo ASCT owing poor mobilization. Identification of mobilizers (PMs) would provide a tool for early intervention with new mobilization agents. The Gruppo italianoTrapianto di Midollo Osseo working group proposed definition PMs applicable clinical trials practice. analytic hierarchy process, method decision making, was used in setting prioritized criteria. Lymphoma or were defined as 'proven PM' when: (1) after adequate (G-CSF 10 μg/kg if alone...
High-dose chemotherapy with peripheral blood progenitor cell (PBPC) autograft is effective in high-risk lymphoma, particularly the addition of rituximab; however, it associated risk secondary malignancy. These issues have been addressed a series 1,347 patients lymphoma treated high-dose sequential (HDS) program.A total 1,024 B-cell 234 Hodgkin's and 89 T-cell were HDS between 1985 2005 at 11 Gruppo Italiano Terapie Innovative Linfomi centers. was given as salvage treatment to 707 (52%); 655...
BackgroundGene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of stromal signatures remains limited.Patients and methodsHere, we applied computational method CIBERSORT to generate 1028-gene matrix incorporating 17 immune cytotypes. Then, carried out deconvolution on publicly available GEP data 482 untreated DLBCLs reveal associations between clinical outcomes proportions...
Treatment of secondary CNS dissemination in patients with aggressive lymphomas remains an important, unmet clinical need. Herein, we report the final results a multicenter phase II trial addressing new treatment for lymphoma based on encouraging experiences high doses antimetabolites primary and rituximab plus high-dose sequential chemoimmunotherapy (R-HDS) relapsed lymphoma.HIV-negative B-cell involvement at diagnosis or relapse, age 18 to 70 years, Eastern Cooperative Oncology Group...
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways surrounding microenvironments diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups their underlying genomic abnormalities, pathway signatures, microenvironment compositions uncover biomarkers therapeutic vulnerabilities. studied 303 spleen samples...
Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets patients lacking, especially relapsed or refractory leukemia.AVALON a multicentric cohort study that was conducted Italy AML who received venetoclax-based therapies from 2015 to 2020. The approved by ethics committee participating institution and accordance Declaration Helsinki. effectiveness toxicity venetoclax + HMA 190 (43 newly...
The role of first-line single-agent rituximab immunotherapy in follicular lymphoma (FL) remains debated, as most patients eventually undergo chemotherapy. In this study, we retrospectively analyzed 81 FL treated with monotherapy (n = 53) or without 28) consolidation. Fifty-one (63%) were high-tumor burden according to Group d'Etude des Lymphomes Folliculaires (GELF) criteria. After a median follow-up 11 years, overall survival (OS) and progression-free (PFS) rates 85% 32%, respectively....